Polar Capital LLP lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 225,000 shares of the biopharmaceutical company’s stock after acquiring an additional 24,896 shares during the quarter. Polar Capital LLP’s holdings in Gilead Sciences were worth $14,074,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of GILD. BlackRock Inc. increased its stake in Gilead Sciences by 2.2% during the 4th quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock worth $6,516,839,000 after buying an additional 2,195,948 shares during the period. Vanguard Group Inc. increased its stake in Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after buying an additional 1,071,619 shares during the period. Vanguard Group Inc increased its stake in Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after buying an additional 1,071,619 shares during the period. Capital Research Global Investors increased its stake in Gilead Sciences by 22.5% during the 3rd quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock worth $5,393,502,000 after buying an additional 12,818,301 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Gilead Sciences by 199,789.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after buying an additional 31,335,030 shares during the period. Hedge funds and other institutional investors own 80.13% of the company’s stock.
Several equities research analysts recently weighed in on GILD shares. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Friday. Oppenheimer raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research report on Thursday, January 3rd. Wells Fargo & Co dropped their price objective on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 5th. Finally, BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $82.29.
NASDAQ GILD opened at $63.77 on Monday. The company has a current ratio of 3.38, a quick ratio of 3.30 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $81.34 billion, a P/E ratio of 10.37, a P/E/G ratio of 4.01 and a beta of 1.16. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period last year, the business earned $1.78 earnings per share. On average, research analysts forecast that Gilead Sciences, Inc. will post 6.23 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.95%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.
In related news, Director John Francis Cogan sold 2,700 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total value of $175,689.00. Following the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at approximately $3,745,429.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the sale, the director now owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The disclosure for this sale can be found here. Company insiders own 1.16% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Stake Boosted by Polar Capital LLP” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://transcriptdaily.com/2019/03/25/gilead-sciences-inc-gild-stake-boosted-by-polar-capital-llp.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Recommended Story: How does inflation affect different investments?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.